Interest from the nicotine-alternatives industry in US president-elect Donald Trump’s pick for Food and Drug Administration (FDA) commissioner, Martin Makary, is less about who he is and more about who he is not.
Many industry members are fed up with multi-term incumbent Robert Califf, who they perceive as a significant roadblock in the process for approving new tobacco products and a general opponent of vaping as well as other reduced-risk categories.
